Recent Updates
Recently added Catalysts

GEN1286

Phase 2

Advanced Solid Tumor | Small molecule | Oncology |Genmab A/S|Last Updated: Mar 2, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment23
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06685068A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid TumorsPHASE1/PHASE2 ACTIVE NOT_RECRUITING 23 — — Nov 1, 2024Jun 1, 2028Mar 2, 2026 - —
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
GEN1286DRUGSpecified dose on specified days.
Unlock Study Design Details
Competitive Landscape -Other Solid Tumors 9 trials
CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK2PHASE2pembrolizumab, V503, GARDASIL
Incyte CorporationINCY1PHASE2Chemotherapy, Retifanlimab
Novartis AG Sponsored ADRNVS1PHASE1KFA115, pembrolizumab
Iovance Biotherapeutics IncIOVA2PHASE2E7 TCR-T cells, Aldesleukin
AstraZeneca PLCAZN1 — Trastuzumab deruxtecan
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT06685068studyFirstPostDate: changed